Tweet
Bank of New York Mellon Corp cut its holdings in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 24.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 636,290 shares of the medical equipment provider's stock after selling 207,968 shares during the period. Bank of New York Mellon Corp owned about 1.43% of ABIOMED worth $260,274,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. BB&T Securities LLC grew its position in ABIOMED by 11.8% during the 1st quarter. BB&T Securities LLC now owns 1,310 shares of the medical equipment provider's stock worth $381,000 after acquiring an additional 138 shares during the last quarter. Commonwealth Equity Services LLC grew its position in ABIOMED by 4.9% during the 1st quarter. Commonwealth Equity Services LLC now owns 3,093 shares of the medical equipment provider's stock worth $900,000 after acquiring an additional 145 shares during the last quarter. M&T Bank Corp boosted its position in ABIOMED by 14.4% in the 1st quarter. M&T Bank Corp now owns 1,355 shares of the medical equipment provider's stock valued at $394,000 after buying an additional 171 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in ABIOMED by 2.3% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 8,993 shares of the medical equipment provider's stock valued at $2,617,000 after buying an additional 206 shares during the last quarter. Finally, Advisor Partners LLC boosted its position in ABIOMED by 26.4% in the 2nd quarter. Advisor Partners LLC now owns 1,057 shares of the medical equipment provider's stock valued at $432,000 after buying an additional 221 shares during the last quarter. Institutional investors and hedge funds own 87.50% of the company's stock. Get ABIOMED alerts:
Shares of ABMD opened at $368.97 on Friday. The firm has a market capitalization of $16.96 billion, a price-to-earnings ratio of 150.60, a PEG ratio of 4.06 and a beta of -0.02. ABIOMED, Inc. has a 52 week low of $144.01 and a 52 week high of $450.93. ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings data on Thursday, July 26th. The medical equipment provider reported $1.95 EPS for the quarter, beating the Zacks' consensus estimate of $0.80 by $1.15. The firm had revenue of $180.01 million for the quarter, compared to analyst estimates of $173.87 million. ABIOMED had a return on equity of 18.91% and a net margin of 25.71%. The business's quarterly revenue was up 35.9% compared to the same quarter last year. During the same period last year, the company earned $0.82 EPS. equities research analysts predict that ABIOMED, Inc. will post 3.45 earnings per share for the current fiscal year.
A number of research analysts have commented on ABMD shares. Jefferies Financial Group increased their price objective on ABIOMED to $460.00 and gave the company a "buy" rating in a research report on Tuesday, May 29th. Piper Jaffray Companies increased their price objective on ABIOMED from $360.00 to $480.00 and gave the company an "overweight" rating in a research report on Friday, June 22nd. Zacks Investment Research lowered ABIOMED from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 3rd. BidaskClub lowered ABIOMED from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, June 26th. Finally, ValuEngine upgraded ABIOMED from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 3rd. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of "Buy" and an average target price of $374.88.
In other news, COO David M. Weber sold 19,282 shares of the stock in a transaction on Monday, July 30th. The stock was sold at an average price of $356.77, for a total value of $6,879,239.14. Following the transaction, the chief operating officer now owns 167,124 shares of the company's stock, valued at approximately $59,624,829.48. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website . Also, Chairman Michael R. Minogue sold 105,000 shares of the stock in a transaction on Thursday, June 21st. The shares were sold at an average price of $439.69, for a total value of $46,167,450.00. Following the completion of the transaction, the chairman now directly owns 481,150 shares in the company, valued at approximately $211,556,843.50. The disclosure for this sale can be found here . In the last three months, insiders sold 170,782 shares of company stock worth $73,628,984. 3.50% of the stock is currently owned by company insiders.
About ABIOMED
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Featured Story: Marijuana Stocks Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter 